Dimorphic association of dopaminergic transporter gene variants with treatment outcome: Pilot study in Indian ADHD probands

详细信息    查看全文

• 作者：Anirban Ray<sup>1sup><sup> ; sup><sup>2sup><sup> ; sup><sup>dranirbanray@gmail.comsup> ; Subhamita Maitra<sup>2sup><sup> ; sup><sup>msubhamita4u@yahoo.comsup> ; Mahasweta Chatterjee <sup>mahaswetachatterjee1991@gmail.comsup> ; Paramita Ghosh <sup>mail2paromitaa@yahoo.comsup> ; Arijit Karmakar <sup>research.arijitkarmakar@gmail.comsup> ; Swagata Sinha <sup>swagata7sinha@hotmail.comsup> ; Kanchan Mukhopadhyay<sup> ; sup><sup>kanchanmvk@yahoo.comsup>
• 关键词：ADHD ; MPH ; ATX ; rs28363170 ; rs3785143 ; rs4680 ; rs1611115
• 刊名：Meta Gene
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：11
• 期：Complete
• 页码：64-69
• 全文大小：438 K
• 卷排序：11

文摘

Pharmaceutical intervention of ADHD mainly targets the dopamine or norepinephrine transporters. Variation in response often leads to treatment discontinuation. A few gene variants were analyzed to identify their association with response to medication. MPH induced more pronounced side effects though reduced behavioural problems (P= 0.005) as compared to ATX. DA and NE transporter variants affected MPH and ATX induced improvements differently (Cohen&rsquo;s d > 0.80; Add value > 8.0). Efficacy of MPH will be more for subjects with rs28363170 10R / rs3785143 T, while ATX may provide relief in presence of rs28363170 9R / rs3785143 C.